Medtronic Infuse Bone Graft Cancer Concerns Raised by New Study

Medtronic’s Infuse bone graft product could be linked to an increased risk of cancer, according to the findings of a new study. 

As a result of research presented last week at the North American Spine Society, there is growing concerns over a potential risk of cancer from Medtronic Infuse, which contains rhBMP-2, a bioengineered bone growth protein

Researchers indicate that a higher-dose formulation of the Infuse, known as Amplify, has been linked to a significantly higher number of cancers than were found among those who received a traditional bone graft.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

Patients implanted with rhBMP-2 were 2.5 times more likely to develop cancer within the next year than those who were not implanted with the bone growth product, according to the study’s findings. That risk increased fivefold after three years.

Types of cancer linked to Medtronic Infuse bone growth could include breast cancer, pancreatic cancer and prostate cancer.

While researchers indicate that Infuse is probably not a carcinogen itself, if it is linked to a higher cancer risk, it is probably as a cancer promoter.

The study, which has not yet been published, was headed by Dr. Eugene Carragee, editor-in-chief of the Spine Journal and a professor at Stanford University School of Medicine. Carragee authored a report in June that found that 10% to 50% of Infuse recipients experienced complications during the clinical trials, including cancer, pain, infections and sterility. However, those problems were not mentioned in studies published by researchers with financial ties to Medtronic.

Medtronic Infuse is used to encourage bone growth and replace spinal disks by filling the gaps between vertebrae. It was approved by the FDA in 2002 and generated about $900 million in sales for Medtronic in the last fiscal year.

Suspicions about Infuse’s clinical trials have led to inquiries by Congress, and the company is under investigation by the Department of Justice for illegally marketing Infuse for off-label uses.

Scientists first began raising questions when they suspected a link between male sterility and Infuse, but medical researchers who received millions of dollars from Medtronic, claimed they could find no link. Some of those researchers later revealed that out of six cases of reported sterility noted during clinical trials, five of those were men treated with Infuse.

Besides fears of sterility and cancer, Medtronic Infuse side effects are also suspected of including serious and life-threatening complications caused by airway compression when used “off-label” in the cervical spine.

A number of patients have had to receive respiratory support tracheotomies, insertion of feeding tubes, anti-inflammatory medications and additional surgery after experiencing problems with Medtronic Infuse after a cervical spine surgery.

This has often been caused by swelling of the neck and led to an FDA warning to healthcare providers in July 2008 that highlighted at least 38 reports of cervical spine fusion problems with Infuse. Most of these Medtronic Infuse problems occurred within 2 to 14 days after surgery.

2 Comments

  • DanielleFebruary 15, 2013 at 5:58 am

    I had anterior approach spinal fusion in 2002 withvthis product. In 2005 I was diagnosed with thymoma tumor in my chest....I was only 33 years old, i am wondering if this tumor was caused by the bone growth promotwe product??? Any advice? I underwent open heart thoracic surgery to remove the tumor abd still suffer today.

  • LynnJuly 15, 2012 at 3:47 am

    My husband had an antierior and postieror fusion of the L2 to S1 in June 2009, a bone graft was used- not from his hip a bone stimulator graft was used - we were never told who manufactured it. We were told that there was a risk to retrograde ejaculation and sterility and at our age - that was not a concern. In March of this year we were informed my husband had stage IV kidney cancer- his blood wo[Show More]My husband had an antierior and postieror fusion of the L2 to S1 in June 2009, a bone graft was used- not from his hip a bone stimulator graft was used - we were never told who manufactured it. We were told that there was a risk to retrograde ejaculation and sterility and at our age - that was not a concern. In March of this year we were informed my husband had stage IV kidney cancer- his blood work panels at that time were perfect- he had no symptoms. My husband was put on oral chemo drugs - unfortunately they did not help and he passed away within 105 days of diagnosis. I am following up with an attorney to see if this is the reason that his cancer was so agressive and deadly. He survived 3 years and 15 days post surgery and he was only 56 years old.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gardasil Lawsuits Over Failure To Warn Doctors About HPV Vaccine Risks Cleared To Move Forward
Gardasil Lawsuits Over Failure To Warn Doctors About HPV Vaccine Risks Cleared To Move Forward (Posted today)

A federal judge has cleared Gardasil lawsuits to move forward, after paring down plaintiffs' claims to those alleging Merck either failed to warn, or fraudulently concealed, the HPV vaccine's risks from the medical community.